Chemical formula: C₁₆H₁₃N₃O₃ Molecular mass: 295.293 g/mol PubChem compound: 4030
Mebendazole interacts in the following cases:
Concomitant treatment with cimetidine may inhibit the metabolism of mebendazole in the liver, resulting in increased plasma concentrations of the drug.
Since mebendazole is contraindicated in pregnancy, patients who think they are, or may be, pregnant should not take this preparation.
Limited data from case reports demonstrate that a small amount of mebendazole is present in human milk following oral administration. Therefore, caution should be exercised when mebendazole is administered to breast-feeding women.
Mebendazole has no influence on the ability to drive and use machines.
Adverse reactions are adverse events that were considered to be reasonably associated with the use of mebendazole based on the comprehensive assessment of the available adverse event information. A causal relationship with mebendazole cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of mebendazole was evaluated in 6276 subjects who participated in 39 clinical trials for the treatment of single or mixed parasitic infestations of the gastrointestinal tract. In these 39 clinical trials, no adverse drug reactions (ADRs) occurred in ≥1% of mebendazole-treated subjects.
ADRs identified from clinical trials and post-marketing experience with mebendazole are included in the following table. The displayed frequency categories use the following convention:
Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1000 to <1/100); Rare (≥1/10,000 to <1/1000); Very rare (<1/10,000), Not known (cannot be estimated from the available data).
Adverse Drug Reactions Reported in Clinical Trials and Post-marketing Experience for mebendazole:
| System Organ Class | Adverse Drug Reactions | ||
|---|---|---|---|
| Frequency Category | |||
| Common (≥1/100 to <1/10) | Uncommon (≥1/1000 to <1/100) | Rare (≥1/10,000 to <1/1000) | |
| Blood and Lymphatic System Disorders | Neutropeniab Agranulocytosisb* | ||
| Immune System Disorders | Hypersensitivity including anaphylactic reaction and anaphylactoid reactionb | ||
| Nervous System Disorders | Convulsionsb Dizzinessa | ||
| Gastrointestinal Disorders | Abdominal paina | Abdominal discomforta; Diarrhoeaa; Flatulencea Nauseaa, Vomitinga | |
| Hepatobiliary Disorders | Hepatitisb; Abnormal liver function testsb | ||
| Skin and Subcutaneous Tissue Disorders | Rasha Toxic epidermal necrolysisb; Stevens-Johnson syndromeb; Exanthemab; Angioedemab; Urticariab; Alopeciab | ||
| Renal and Urinary Disorders | Glomerulonephritisb* | ||
a ADR frequency data derived from Clinical Trials or Epidemiological Studies
b ADRs not observed in clinical trials and frequency calculated based on 6276 patients exposed in clinical trials and epidemiological studies, divided by 3 (Frequency = 1/2092).
* Observed in higher and prolonged doses
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
